key: cord-0694876-ydyvuvt7 authors: Boschiero, Matheus Negri; Duarte, Aires; Palamim, Camila Vantini Capasso; Alvarez, Alfonso Eduardo; Mauch, Renan Marrichi; Marson, Fernando Augusto Lima title: Frequency of respiratory pathogens other than SARS-CoV-2 detected during COVID-19 testing date: 2021-10-22 journal: Diagn Microbiol Infect Dis DOI: 10.1016/j.diagmicrobio.2021.115576 sha: 25781fd5f7c7f19ac47562415e8d272cf47f43e6 doc_id: 694876 cord_uid: ydyvuvt7 The frequencies of 19 respiratory pathogens other than SARS-CoV-2 were assessed in 6,235 Brazilian individuals tested for COVID-19. Overall, only 83 individuals who tested positive for SARS-CoV-2 had co-detection of other pathogens. Individuals infected with Rhinovirus/Enterovirus, Human Coronavirus (HCoV)-HKU1, HCoV-NL63, HPIV-4, Influenza A (-H1N1 and other subtypes), Influenza B, Human Respiratory Syncytial Virus and Human Metapneumovirus were less likely to test positive for SARS-CoV-2. Infection with Streptococcys pyogenes, Chlamydophila pneumoniae, Mycoplasma pneumoniae and Bordetella pertussis were more frequent in individuals who tested negative for SARS-CoV-2, but without significancy. We found 150 individuals infected with ≥2 pathogens other than SARS-CoV-2, only three out of whom tested positive for COVID-19. The co-detection frequency was low in individuals diagnosed with COVID-19. Other viral infections may provide a cross-reactive, protective immune response against SARS-CoV-2. Screening for bacterial respiratory infections upon COVID-19 testing is important to drive suitable therapeutic approaches and avoid unnecessary antibiotic prescription. Screening for different pathogens that can cause symptoms similar to COVID-19 is important for driving appropriate disease-specific measures, and co-detection of other viruses such as Rhinoviruses, Influenza viruses, other human Coronaviruses and Adenoviruses has been reported during SARS-CoV-2 testing [1] [2] [3] [4] . Unlike COVID-19, the diagnosis of several respiratory viral infections is usually based on clinical history and physical examination, with no additional laboratory tests being required, even though it is possible to use reverse transcriptase real-time polymerase chain reaction (RT-PCR) to identify the causative pathogen [5] . In addition, bacterial and fungal pathogens have also been co-detected during SARS-CoV-2 testing, such as Streptococcus pneumoniae, Klebsiella pneumoniae, Staphylococcus aureus and Aspergillus sp. [1] [2] [3] [4] . For this reason, we aimed to describe the frequency of microorganisms other than SARS-CoV-2 detected during COVID-19 testing in a Brazilian cohort. We used data obtained from the COVID-19 Data Sharing/BR database, an initiative of the São Paulo Research Foundation (FAPESP) [6] , in conjunction with five public and private health services This database is available at https://repositoriodatasharingfapesp.uspdigital.usp.br/. The included individuals were first grouped according to sex and age range. Clinical outcomes, such as hospitalization or death, were described only by Hospital Sírio-Libanês. SARS-CoV-2 detection was done using RT-PCR and the patients were classified as positive and negative for SARS-CoV-2. The different protocols for RT-PCR testing were not detailed in the datasets. The following viruses were screened together with SARS-CoV-2: Influenza A viruses (-H1N1 and other subtyes), Influenza B virus, Human Respiratory Syncycial Virus (HRSV), Human Type I (HPIV-1), II (HPIV-2), III (HPIV-3), IV (HPIV-4 pneumoniae were detected using a molecular panel for detection of respiratory pathogens. Serological tests for detection of specific IgM and IgG were also used to detect M. pneumoniae and C. pneumoniae. The datasets did not describe the reference or brands of the diagnostic kits for bacterial infections. Detection of yeasts in urine was made using microscopic examination of the first urine sample of the day during routine urinalysis. Databases for the present study were provided by Fleury Institute, Hospital Israelita Albert Einstein (two MS Excel files each, one with demographic data and one with clinical data and test results). Hospital Sírio-Libanês provided three MS Excel sheets, one with demographic information, one with test results and one with the clinical data, including outcomes. Using the KNIME software [7], patients' information and medical results datasets were innerjoined by patient ID [8]. Data on patients' outcomes from Hospital Sírio-Libanês Hospital were later inner-joined by patient and attendance ID. These three datasets were processed by a string manipulation module to remove diacritics and transform every word to lowercase [9]. RT-PCR results were split by a row splitter module and inner-joined by patient ID and medical exam date [8,10]. These three datasets were then exported as an .CSV file [11] . Using the R software [12], the three datasets were read, and rowbound together using the rbind.fill function [13] . Different words associated to the same meaning were normalized along the dataset. Results for repetition, inconclusive results and empty results were removed by the filter. Medical exams, with the exception of testing for microorganisms, were also removed by the same function [14] . Demographic characteristics and data on laboratory exams performed on the day of respiratory sampling for COVID-19 investigation were included in the first screening stage. The second screening stage included cases where at least one respiratory pathogen was investigated in addition to SARS-CoV-2 (Figure 1 ). The data were described as absolute and relative frequencies when categorizing individuals according to sex, age, presence of COVID-19, database source, patient outcome and presence of other microorganisms. Difference in the proportions between two groups or among more than two groups were assessed using the Pearson Chi-square test or Fisher Exact Test. Associations between variables were analyzed using odds ratio (OR) and their correspondent 95% confidence intervals [12, 14, 15] . For all tests, a p-value ≤ 0.05 indicated statistical significance. The analyses were performed using the R software. Data of 73,897 individuals were included in the first screening, out of whom 16,850 (22.8%) tested positive to SARS-CoV-2. Among the individuals, 6,235 (8.44%) people were screened for at least one microrganism in addition to SARS-CoV-2. In the final cohort, the majority of individuals were female (3,049/6,235; 51.10%) and aged between 25 and 61 years old (yo) ( Overall, 1,420 out 1,503 (94.5%) individuals with a negative COVID-19 test tested positive for at least one microorganism, 755 of whom were 25-60 yo, 401 were 1-12 yo, 155 were 13-24 yo, 66 were 61-72 yo, 32 were 73-85 yo, seven were <1 yo and three were more than 85 yo. Among individuals with a positive COVID-19 test, 83 out of 1,503 (5.5%) tested positive for at least one additional microorganism, 38 of whom were 25-60 yo, seven were 1-12 yo, nine were 13-24 yo, 26 were 61-72 yo, three were 73-85 yo and one was older than 85 yo ( Table 2) . We identified 150 cases of co-detection of more than one microorganism other than SARS-CoV-2 and grouped them into 55 microbiological profiles. Three cases were individuals who tested positive for SARS-CoV-2, one of whom tested positive for 16 microrganims. Of note, we are not able to state whether this was a database error, or if all microorganisms were true pathogens, and this finding should therefore be looked at with caution. One individual tested positive for three microorganisms and had yeasts in the urine, and one tested positive for three microorganisms without having yeasts in the urine ( Table 3) . Among individuals not diagnosed with COVID-19, one tested positive for four microorganisms, 14 tested positive for three microorganisms and 132 tested positive for two microorganisms ( Table 3) . Overall, we found 95 cases of co-detection with RV/EV, 43 with Influenza A-H1N1 virus, 28 with Influenza B virus, 27 with HRSV and 21 with HCoV-NL63 (SM-3). Notably, most individuals in our cohort who were infected with other respiratory viruses tested negative for SARS-CoV-2, and, in a cross-sectional analysis, nine viruses had their presence associated with a lower risk of testing positive for SARS-CoV-2, among which HCoVs -NL63 and -HKU1, two coronaviruses that cause the common cold, are worth highlighting. In a cohort with more than 800,000 individuals in Israel, individuals aged more than 18 yo who had common cold symptoms in the year before the COVID-19 pandemic were shown to have a lower risk of having COVID-19 [16] , which was suggested to be due to past coronavirus infections and is corroborated by studies showing that serum and plasma samples from individuals without COVID-19 reacted against proteins of SARS-CoV-2 and other human coronaviruses in immunofluorescence and flow cytometry assays [17, 18] . Immunity induced by infections with HCoVs -NL63 and -HKU1 may have provided individuals in our cohort with a protective, cross-reactive response against SARS-CoV-2. This association was not significant for HCoVs -229E and -OC43, but most individuals infected with these coronaviruses also tested negative for COVID-19. As there were fewer of these individuals, one can speculate that the impact of HCoV -229E and -OC43 infections has been underestimated. Most of the co-detected pathogens in individuals who tested positive for SARS-CoV-2 reported here were viruses. Overall, 1,334 (88.88%) individuals tested positive for other viruses, with RV/EV being the most common one (44.1%), which is in accordance with the literature [19] . Testing positive for HPIV-4, Influenza A, Influenza A-H1N1, Influenza B viruses, hMPV, HSRv and RV/EV were associated with a lower risk of testing positive for SARS-CoV-2. Coronaviruses have molecular structures that are similar to Influenza viruses [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] , possibly leading to cross-reactivity between the two viral groups [23] . RV/EV and HRSV also have some degree of similarity with SARS-CoV-2, but they have been shown to be poor sources of cross-reactivity [24] . Thus, a different mechanism may be associated with the low SARS-CoV-2 positive testing rate among patients infected with these viruses. In a study performed at the Icahn School of Medicine (New York, USA), with 8,990 individuals tested for SARS-CoV-2, 1,204 individuals tested positive for other respiratory viruses, and co-detection was found in only 36 (<3%) individuals. On the other hand, co-detection with at least one respiratory viral pathogen other than SARS-CoV-2 was found in 13.1% of individuals who tested negative for SARS-CoV-2. Additionally, in patients who tested negative for SARS-CoV-2, the most common respiratory viral codetections were community-acquired [29] . Worse outcomes have been reported, especially when codetection happened with Influenza viruses [22, 25, 26] , which resulted in a more detrimental immune response [27, 28] . That seems not to be the case in our cohort, as none of the individuals with severe or fatal outcomes were infected with pathogens other than SARS-CoV-2. Even though most studies evaluating bacterial co-detection used RT-PCR for bacterial detection [30] [31] [32] [33] , some reports used serological tests to detect the presence of bacterial antigens [26, 34] , as was the case with individuals of our cohort. Most individuals who had bacterial respiratory infection did not test positive for COVID-19, which has been shown by other studies [1, 19] . This raises concern whether many bacterial respiratory infections are neglected in the diagnostic routine and underlines the need for more accurate diagnostic tools targeting these infections, especially in the current pandemic setting, as they also cause symptoms that resemble COVID-19. Overall, the impact of bacterial co-detection in COVID-19 is not fully clear. In a study, performed at a hospital in the Jiangsu Province (China), with 257 individuals with COVID-19, bacterial co-detections were dominant in all COVID-19 cases, with S. pneumoniae being the most common pathogen, followed by K. pneumoniae and H. influenzae. Moreover, patients with viral co-detections and bacterial-fungal co-detections were shown to be the most severe COVID-19 cases [2] . Some studies have shown that bacterial and fungal co-detection may be associated with more severe lung injury [28, 35] , a 2.5-fold increased risk of death and can impair the diagnosis, treatment, and prognosis of the disease [28, 36] . In our study, like previously described [1, 37] , the frequency of bacterial co-detection was low and not shown to be associated with worse COVID-19related outcomes. It is worth mentioning that irrational antibiotic prescribing has become a major problem when managing COVID-19. A recent metanalysis assessing data of more than 30,000 patients with COVID-19 all over the world found that nearly 75% of them received antibiotics, which was significantly higher than their 8.6% estimated rate of bacterial infection. Although there is no information on treatment in the COVID-19 Data Sharing/BR database, our finding that only a low number of patients had bacterial infection highlights that the empirical use of antibiotics in patients with COVID-19 should not be recommended, as also observed by previous reports [38] [39] [40] . It is noticeable that the presence of yeasts in urine was more frequent in individuals in our cohort who tested positive for COVID-19. Previous studies have reported fungemia in patients with COVID-19 who were hospitalized [41, 42] , which may corroborate our findings. Lymphopenia is present in most patients with COVID-19 [43] and can play a role, as the lymphocyte response is essential against fungal infections [44] . Unfortunately, there were no data on fungemia in the COVID-19 Data Sharing/BR database, so we were not able to conduct a deeper investigation into this matter. A thorough screening for COVID-19 is not only important to avoid overload in public health units but can also be used for screening for other community-acquired respiratory infections. It is concerning that only 37% of the individuals that were screened from the COVID-19 Data Sharing/BR database have been tested for respiratory pathogens other than SARS-CoV-2. Besides, since identification of respiratory pathogens other than SARS-CoV-2 is not routinely performed, this number is likely to be underestimated. Importantly, these individuals were seen in high-standard Brazilian health care institutions, which, unlike most public health services in Brazil, have the facilities and financial resources needed to perform these kinds of tests. This underlines the inequality in the access to tests that could detect varied respiratory infections, especially the bacterial ones, which, in turn, could help to drive better treatment strategies. Our study has several limitations, including its retrospective design, with most data being restricted to a single hospital. A longitudinal monitoring of the individuals in the cohort was not possible. Co-detection was uncommon in patients who tested positive for SARS-CoV-2. HCoV-HKU1, HCoV-NL63, HPIV-4, Influenza A virus, Influenza A-H1N1 virus, Influenza B virus, hMPV, HSRV and RV/EV were associated with a lower risk of testing positive for SARS-CoV-2. Even though the screening for COVID-19 is beneficial, it is unfeasible for the Brazilian public health system to afford a thorough screening for other respiratory pathogens, making clinical history and physical examination the firstchoice methods. All individuals who had a negative test for SARS-CoV-2 went to the hospital to do the test, stressing the need for a protocol for requirement of SARS-CoV-2 RT-PCR to prevent unnecessary exposure to the virus upon spontaneous appearances in the testing center. Table 1 . Demographic data from the individuals included in the study. Legend: *, 13 exams were performed in individuals whose ages were not informed, two of whom were individuals with COVID-19, both of whom were cases of yeasts in urine, and 11 were individuals without COVID-19, (six cases of Rhinovirus/Enterovirus infection, three cases of yeasts in urine and one case of Influenza B infection). The data are associated with the number of exams performed. Table 3 . Co-detection profile (more than two microorganisms other than SARS-CoV-2) in individuals with COVID-19 symptoms with and without SARS-CoV-2 infection. *, Of note, we reviewed several times, in the same dataset, the data of the individual who tested positive for 16 microrganisms, and the same result was given. The conclusions about this finding should therefore be careful. Co-infection with other respiratory pathogens in COVID-19 patients Co-infection with respiratory pathogens among COVID-2019 cases Coinfection of SARS-CoV-2 and Other Respiratory Pathogens Identification of SARS-CoV-2 and additional respiratory pathogens cases under the investigation of COVID-19 initial phase in a Brazilian reference laboratory The Common Cold. Mand Douglas Bennetts Princ Pract Infect Dis Opening Brazilian COVID-19 patient data to support world research on pandemics The Konstanz Information Miner The R Project for Statistical Computing The Split-Apply-Combine Strategy for Data Analysis dplyr: A Grammar of Data Manipulation Prior presumed coronavirus infection reduces COVID-19 risk: A cohort study Preexisting and de novo humoral immunity to SARS-CoV-2 in humans High prevalence of preexisting serological cross-reactivity against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) in sub-Saharan Africa Rates of Co-infection Between SARS-CoV-2 and Other Respiratory Pathogens Structure of coronavirus hemagglutinin-esterase offers insight into corona and influenza virus evolution Structure of a paramyxovirus polymerase complex reveals a unique methyltransferase-CTD conformation Influenza immunization and COVID-19 Immune responses in influenza A virus and human coronavirus infections: an ongoing battle between the virus and host Potential Cross-Reactive Immunity to SARS-CoV-2 From Common Human Pathogens and Vaccines Co-infection with COVID-19 and influenza A virus in two died patients with acute respiratory syndrome Clinical characteristics of critically ill patients co-infected with SARS-CoV-2 and the influenza virus in Wuhan, China The trinity of COVID-19: immunity, inflammation and intervention The microbial coinfection in COVID-19 Coinfection in SARS-CoV-2 infected patients: Where are influenza virus and rhinovirus/enterovirus? Bacterial and viral co-infections in patients with severe SARS-CoV-2 pneumonia admitted to a French ICU Clinical Characteristics of Patients Hospitalized with Coronavirus Disease Analysis of factors associated with disease outcomes in hospitalized patients with 2019 novel coronavirus disease Bacterial coinfection and secondary infection in patients with COVID-19: a living rapid review and meta-analysis Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan Lymphopenia predicts disease severity of COVID-19: a descriptive and predictive study Factors associated with mortality in patients with COVID-19. A quantitative evidence synthesis of clinical and laboratory data Coinfections with SARS-CoV-2 and other respiratory pathogens Effect of Oral Azithromycin vs Placebo on COVID-19 Symptoms in Outpatients With SARS-CoV-2 Infection: A Randomized Clinical Trial Azithromycin for community treatment of suspected COVID-19 in people at increased risk of an adverse clinical course in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial Antibiotic prescribing in patients with COVID-19: rapid review and meta-analysis Fungemia in COVID-19 ICU patients, a single medical center experience Oropharyngeal candidiasis in hospitalised COVID-19 patients from Iran: Species identification and antifungal susceptibility pattern Laboratory findings in COVID-19 diagnosis and prognosis Table 3 . Microorganism profile for the co-detection (more than two without taking into account the SARS-CoV-2) in individuals with COVID-19 symptoms regarding the SARS-CoV-2 infection.